China's rapid rise as a source of innovative cancer drugs is attracting a steady flow of capital, and one of the newest beneficiaries is a young company developing a sophisticated class of targeted therapies.
Phrontline Biopharma has raised nearly $40 million in a Series A funding round co-led by Yuanhe Origin and Decheng Capital, with participation from Longpan, Jifeng and other investors, according to TechStartups, which listed the deal in its funding roundup published on Friday, November 13. The announcement fell on November 12 in US Eastern time and November 13 in China.
The round follows a $60 million Pre-A+ round announced in November 2025, led by Lapam Investment, with participation from Samsung Venture Investment Corporation, Sino Biopharmaceutical and others, according to Pulse 2.0. Decheng Capital was an existing investor that increased its commitment in that round.
What Phrontline develops
Phrontline, founded in 2022 by chief executive Tony Chen, focuses on bispecific and dual-payload antibody-drug conjugates (ADCs), according to Pulse 2.0. Its platform covers antibody discovery, linker and payload engineering, site-specific conjugation and functional testing.
Nearly ten ADC candidates have emerged from the platform. The lead programme, TJ101, is a bispecific ADC targeting two proteins found on cancer cells, EGFR and B7-H3, and is enrolling patients in first-in-human clinical trials in China and the United States.
How ADCs work
Antibody-drug conjugates are sometimes described as "guided missiles" for cancer treatment. They combine an antibody, which recognises and binds to a specific protein on the surface of cancer cells, with a potent cell-killing drug, known as the payload, connected by a chemical linker. The antibody delivers the drug directly to cancer cells, aiming to kill them while sparing healthy tissue and reducing the side effects of traditional chemotherapy.
Several ADCs have become blockbuster drugs, including AstraZeneca and Daiichi Sankyo's Enhertu, used to treat breast and other cancers.
The next generation
Phrontline is working on two advances in ADC technology. Bispecific ADCs use antibodies that recognise two different targets on cancer cells, which can improve how specifically they bind to tumours and help overcome the ability of cancers to evade single-target drugs. Dual-payload ADCs carry two different cell-killing drugs, which could make them more effective against tumours that develop resistance to one drug.
Both approaches are technically complex, and they are being pursued by many large pharmaceutical companies and biotech startups worldwide.
Global partnerships
Phrontline has already struck partnerships with larger companies. In October 2025, it began a collaboration with South Korea's Samsung Bioepis to co-develop two bispecific and dual-payload ADC candidates, according to Pulse 2.0. Also in October 2025, Sino Biopharmaceutical licensed exclusive rights to TJ101 in mainland China and Hong Kong.
Such partnerships provide funding and validation for young biotech companies, and are a common route for Chinese biotechs to commercialise their drugs.
China's biotech boom
China has become a major source of innovative drugs, particularly in oncology and ADCs. Global pharmaceutical companies have struck a growing number of licensing deals with Chinese biotechs, paying large upfront and milestone payments for the rights to develop drugs outside China. Chinese companies can often run clinical trials faster and at lower cost, and they have built strong capabilities in antibody engineering and ADC chemistry.




